Corporate ActionJul 29, 2026, 06:51 PM
Vogenx Files for IPO of 6.25M Shares at $11.00-$13.00
AI Summary
Vogenx, Inc. has filed an S-1/A registration statement for its initial public offering, proposing to offer 6,250,000 shares of common stock at an expected price range of $11.00 to $13.00 per share. The company, a clinical-stage biopharmaceutical firm, aims to list its common stock on the Nasdaq Capital Market under the symbol "VOGX." Net proceeds, estimated at $67.8 million, will fund the continued development of its lead product candidate, mizagliflozin, for conditions like post-bariatric hypoglycemia and gastroparesis, and for general corporate purposes.
Key Highlights
- Vogenx is offering 6,250,000 shares of common stock in its initial public offering.
- The expected initial public offering price is between $11.00 and $13.00 per share.
- Underwriters have a 45-day option to purchase up to 937,500 additional shares.
- Estimated net proceeds from the offering are approximately $67.8 million, or $78.2 million if the option is fully exercised.
- Shares outstanding after the offering will be 13,905,643 (or 14,843,143 if option exercised).
- The company has raised approximately $11.5 million in funding from investors since inception.
- Lead product candidate, mizagliflozin, is in Phase 2b for Post-Bariatric Hypoglycemia (PBH), with screening expected to begin in 2026.
- A Phase 2 clinical trial for gastroparesis is planned for initiation in 2027, subject to additional funding.